214 related articles for article (PubMed ID: 15124680)
1. Novel treatment strategies in follicular lymphoma.
Buske C; Dreyling H; Unterhalt M; Hiddemann W
Ann Hematol; 2004; 83 Suppl 1():S72. PubMed ID: 15124680
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
3. Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas.
Domingo-Domènech E; González-Barca E; Estany C; Sureda A; Besalduch J; Fernández de Sevilla A
Haematologica; 2002 Nov; 87(11):1229-30. PubMed ID: 12414357
[TBL] [Abstract][Full Text] [Related]
4. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B; Santos ES
Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
[TBL] [Abstract][Full Text] [Related]
5. The role of mitoxantrone in the treatment of indolent lymphomas.
Hagemeister F; Cabanillas F; Coleman M; Gregory SA; Zinzani PL
Oncologist; 2005 Feb; 10(2):150-9. PubMed ID: 15709217
[TBL] [Abstract][Full Text] [Related]
6. Rituximab for the treatment of diffuse large B-cell lymphomas.
Held G; Pöschel V; Pfreundschuh M
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1175-86. PubMed ID: 16925484
[TBL] [Abstract][Full Text] [Related]
7. High-dose therapy for follicular lymphoma revisited: not if, but when?
Lister TA
J Clin Oncol; 2003 Nov; 21(21):3894-6. PubMed ID: 14517186
[No Abstract] [Full Text] [Related]
8. [Milestone in healing fatal indolent lymphoma].
Krankenpfl J; 2004; 42(3-4):106-7. PubMed ID: 15311904
[No Abstract] [Full Text] [Related]
9. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
Hainsworth JD; Litchy S; Morrissey LH; Andrews MB; Grimaldi M; McCarty M; Greco FA
J Clin Oncol; 2005 Mar; 23(7):1500-6. PubMed ID: 15632411
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
Zinzani PL; Pulsoni A; Perrotti A; Soverini S; Zaja F; De Renzo A; Storti S; Lauta VM; Guardigni L; Gentilini P; Tucci A; Molinari AL; Gobbi M; Falini B; Fattori PP; Ciccone F; Alinari L; Martelli M; Pileri S; Tura S; Baccarani M
J Clin Oncol; 2004 Jul; 22(13):2654-61. PubMed ID: 15159414
[TBL] [Abstract][Full Text] [Related]
11. Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial--Intergroup Collaborative Study.
Van Oers MH; Hagenbeek A; Van Glabbeke M; Teodorovic I
Ann Hematol; 2002 Oct; 81(10):553-7. PubMed ID: 12424535
[No Abstract] [Full Text] [Related]
12. Clinical trials for malignant lymphoma in Japan.
Tobinai K; Hotta T
Jpn J Clin Oncol; 2004 Jul; 34(7):369-78. PubMed ID: 15342663
[TBL] [Abstract][Full Text] [Related]
13. CHOP chemotherapy followed by Rituximab consolidation as first line treatment in patients with follicular lymphoma. Long-term follow-up of a phase 2 trial.
Jäger G; Quehenberger F; Linkesch W; Neumeister P
Eur J Haematol; 2007 May; 78(5):453-5. PubMed ID: 17419745
[No Abstract] [Full Text] [Related]
14. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
Taskinen M; Karjalainen-Lindsberg ML; Nyman H; Eerola LM; Leppä S
Clin Cancer Res; 2007 Oct; 13(19):5784-9. PubMed ID: 17908969
[TBL] [Abstract][Full Text] [Related]
15. [Recent progress in the therapeutic strategy for follicular lymphoma and mantle cell lymphoma].
Ogura M
Rinsho Ketsueki; 2006 Jun; 47(6):495-512. PubMed ID: 16862978
[No Abstract] [Full Text] [Related]
16. Phase I/II study of the rituximab-EPOCT regimen in combination with granulocyte colony-stimulating factor in patients with relapsed or refractory follicular lymphoma including evaluation of its cardiotoxicity using B-type natriuretic peptide and troponin T levels.
Niitsu N; Khori M; Hayama M; Kajiwara K; Higashihara M; Tamaru J
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):697-702. PubMed ID: 15701858
[TBL] [Abstract][Full Text] [Related]
17. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma.
Bermúdez A; Marco F; Conde E; Mazo E; Recio M; Zubizarreta A
Haematologica; 2000 Aug; 85(8):894-5. PubMed ID: 10942955
[No Abstract] [Full Text] [Related]
18. [Rituximab, a chimeric mouse-human anti-CD20 monoclonal antibody].
Tobinai K
Nihon Rinsho; 2002 Mar; 60(3):468-72. PubMed ID: 11904960
[TBL] [Abstract][Full Text] [Related]
19. New treatment strategies in lymphomas: aggressive lymphomas.
Coiffier B
Ann Hematol; 2004; 83 Suppl 1():S73-4. PubMed ID: 15124681
[TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy with monoclonal antibody of malignant lymphoma].
Ogura M
Nihon Rinsho; 2007 Jan; 65 Suppl 1():545-60. PubMed ID: 17474462
[No Abstract] [Full Text] [Related]
[Next] [New Search]